172 related articles for article (PubMed ID: 19251828)
1. Escitalopram prolonged fear induced by simulated public speaking and released hypothalamic-pituitary-adrenal axis activation.
Garcia-Leal C; Del-Ben CM; Leal FM; Graeff FG; Guimarães FS
J Psychopharmacol; 2010 May; 24(5):683-94. PubMed ID: 19251828
[TBL] [Abstract][Full Text] [Related]
2. Effect of Vortioxetine vs. Escitalopram on Sexual Functioning in Adults with Well-Treated Major Depressive Disorder Experiencing SSRI-Induced Sexual Dysfunction.
Jacobsen PL; Mahableshwarkar AR; Chen Y; Chrones L; Clayton AH
J Sex Med; 2015 Oct; 12(10):2036-48. PubMed ID: 26331383
[TBL] [Abstract][Full Text] [Related]
3. The 5-HT1D/1B receptor agonist sumatriptan enhances fear of simulated speaking and reduces plasma levels of prolactin.
de Rezende MG; Garcia-Leal C; Graeff FG; Del-Ben CM
J Psychopharmacol; 2013 Dec; 27(12):1124-33. PubMed ID: 23325368
[TBL] [Abstract][Full Text] [Related]
4. Escitalopram (10-20 mg/day) is effective and well tolerated in a placebo-controlled study in depression in primary care.
Lepola UM; Loft H; Reines EH
Int Clin Psychopharmacol; 2003 Jul; 18(4):211-7. PubMed ID: 12817155
[TBL] [Abstract][Full Text] [Related]
5. Treatment of abdominally obese men with a serotonin reuptake inhibitor: a pilot study.
Ljung T; Ahlberg AC; Holm G; Friberg P; Andersson B; Eriksson E; Björntorp P
J Intern Med; 2001 Sep; 250(3):219-24. PubMed ID: 11555126
[TBL] [Abstract][Full Text] [Related]
6. Escitalopram alleviates stress-induced Alzheimer's disease-like tau pathologies and cognitive deficits by reducing hypothalamic-pituitary-adrenal axis reactivity and insulin/GSK-3β signal pathway activity.
Wu C; Gong WG; Wang YJ; Sun JJ; Zhou H; Zhang ZJ; Ren QG
Neurobiol Aging; 2018 Jul; 67():137-147. PubMed ID: 29656013
[TBL] [Abstract][Full Text] [Related]
7. Specific effects of escitalopram on neuroendocrine response.
Hawken ER; Owen JA; Hudson RW; Delva NJ
Psychopharmacology (Berl); 2009 Nov; 207(1):27-34. PubMed ID: 19662384
[TBL] [Abstract][Full Text] [Related]
8. Comparison of the effects of citalopram and escitalopram on 5-Ht-mediated neuroendocrine responses.
Nadeem HS; Attenburrow MJ; Cowen PJ
Neuropsychopharmacology; 2004 Sep; 29(9):1699-703. PubMed ID: 15127082
[TBL] [Abstract][Full Text] [Related]
9. Efficacy of escitalopram in the treatment of major depressive disorder compared with conventional selective serotonin reuptake inhibitors and venlafaxine XR: a meta-analysis.
Kennedy SH; Andersen HF; Lam RW
J Psychiatry Neurosci; 2006 Mar; 31(2):122-31. PubMed ID: 16575428
[TBL] [Abstract][Full Text] [Related]
10. The effects of six-day SSRI administration on diurnal cortisol secretion in healthy volunteers.
Ronaldson A; Carvalho LA; Kostich K; Lazzarino AI; Urbanova L; Steptoe A
Psychopharmacology (Berl); 2018 Dec; 235(12):3415-3422. PubMed ID: 30283981
[TBL] [Abstract][Full Text] [Related]
11. Unfavorable smell with citalopram?
Ghanizadeh A
J Clin Psychopharmacol; 2007 Oct; 27(5):528-9. PubMed ID: 17873697
[No Abstract] [Full Text] [Related]
12. Scopolamine augmentation of a newly initiated escitalopram treatment for major depressive disorder: study protocol for a randomized controlled trial.
Zhou J; Wang W; Yang J; Zhu X; Feng L; Xiao L; Wang G
Trials; 2019 Jan; 20(1):33. PubMed ID: 30626409
[TBL] [Abstract][Full Text] [Related]
13. State and trait abnormalities in serotonin function in major depression.
Bhagwagar Z; Whale R; Cowen PJ
Br J Psychiatry; 2002 Jan; 180():24-8. PubMed ID: 11772847
[TBL] [Abstract][Full Text] [Related]
14. Improvements in SSRI/SNRI-induced sexual dysfunction by switching to escitalopram.
Ashton AK; Mahmood A; Iqbal F
J Sex Marital Ther; 2005; 31(3):257-62. PubMed ID: 16020143
[TBL] [Abstract][Full Text] [Related]
15. Two weeks of pretreatment with escitalopram facilitates extinction learning in healthy individuals.
Bui E; Orr SP; Jacoby RJ; Keshaviah A; LeBlanc NJ; Milad MR; Pollack MH; Simon NM
Hum Psychopharmacol; 2013 Sep; 28(5):447-56. PubMed ID: 23776033
[TBL] [Abstract][Full Text] [Related]
16. Effects of oral racemic citalopram on neuroendocrine responses.
Hawken ER; Owen JA; Van Vugt D; Delva NJ
Prog Neuropsychopharmacol Biol Psychiatry; 2006 Jun; 30(4):694-700. PubMed ID: 16563590
[TBL] [Abstract][Full Text] [Related]
17. The pharmacokinetics of escitalopram after oral and intravenous administration of single and multiple doses to healthy subjects.
Søgaard B; Mengel H; Rao N; Larsen F
J Clin Pharmacol; 2005 Dec; 45(12):1400-6. PubMed ID: 16291715
[TBL] [Abstract][Full Text] [Related]
18. Changes in sexual functioning associated with duloxetine, escitalopram, and placebo in the treatment of patients with major depressive disorder.
Clayton A; Kornstein S; Prakash A; Mallinckrodt C; Wohlreich M
J Sex Med; 2007 Jul; 4(4 Pt 1):917-29. PubMed ID: 17627739
[TBL] [Abstract][Full Text] [Related]
19. The effects of an acute serotonergic challenge on brain-gut responses in irritable bowel syndrome patients and controls.
Kilkens TO; Honig A; Fekkes D; Brummer RJ
Aliment Pharmacol Ther; 2005 Nov; 22(9):865-74. PubMed ID: 16225497
[TBL] [Abstract][Full Text] [Related]
20. Escitalopram and paroxetine in the treatment of generalised anxiety disorder: randomised, placebo-controlled, double-blind study.
Baldwin DS; Huusom AK; Maehlum E
Br J Psychiatry; 2006 Sep; 189():264-72. PubMed ID: 16946363
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
